Development of Nanoemulsions for Topical Application of Mupirocin
Mupirocin (MUP) is a topical antibacterial agent used to treat superficial skin infections but has limited application due to in vivo inactivation and plasma protein binding. A nanoemulsion formulation has the potential to enhance the delivery of mupirocin into the skin. MUP-loaded nanoemulsions wer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/378 |
| _version_ | 1797618731779620864 |
|---|---|
| author | Bahjat Alhasso Muhammad Usman Ghori Barbara R. Conway |
| author_facet | Bahjat Alhasso Muhammad Usman Ghori Barbara R. Conway |
| author_sort | Bahjat Alhasso |
| collection | DOAJ |
| description | Mupirocin (MUP) is a topical antibacterial agent used to treat superficial skin infections but has limited application due to in vivo inactivation and plasma protein binding. A nanoemulsion formulation has the potential to enhance the delivery of mupirocin into the skin. MUP-loaded nanoemulsions were prepared using eucalyptus oil (EO) or eucalyptol (EU), Tween<sup>®</sup> 80 (T80) and Span<sup>®</sup> 80 (S80) as oil phase (O), surfactant (S) and cosurfactant (CoS). The nanoemulsions were characterised and their potential to enhance delivery was assessed using an in vitro skin model. Optimised nanoemulsion formulations were prepared based on EO (MUP-NE EO) and EU (MUP-NE EU) separately. MUP-NE EO had a smaller size with mean droplet diameter of 35.89 ± 0.68 nm and narrower particle size index (PDI) 0.10 ± 0.02 nm compared to MUP-NE EU. Both nanoemulsion formulations were stable at 25 °C for three months with the ability to enhance the transdermal permeation of MUP as compared to the control, Bactroban<sup>®</sup> cream. Inclusion of EU led to a two-fold increase in permeation of MUP compared to the control, while EO increased the percentage by 48% compared to the control. Additionally, more MUP was detected in the skin after 8 h following MUP-NE EU application, although MUP deposition from MUP-NE EO was higher after 24 h. It may be possible, through choice of essential oil to design nanoformulations for both acute and prophylactic management of topical infections. |
| first_indexed | 2024-03-11T08:16:38Z |
| format | Article |
| id | doaj.art-2ee08d4e0b84437a852cf3c65f69b3a1 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:16:38Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-2ee08d4e0b84437a852cf3c65f69b3a12023-11-16T22:39:08ZengMDPI AGPharmaceutics1999-49232023-01-0115237810.3390/pharmaceutics15020378Development of Nanoemulsions for Topical Application of MupirocinBahjat Alhasso0Muhammad Usman Ghori1Barbara R. Conway2Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UKDepartment of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UKDepartment of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UKMupirocin (MUP) is a topical antibacterial agent used to treat superficial skin infections but has limited application due to in vivo inactivation and plasma protein binding. A nanoemulsion formulation has the potential to enhance the delivery of mupirocin into the skin. MUP-loaded nanoemulsions were prepared using eucalyptus oil (EO) or eucalyptol (EU), Tween<sup>®</sup> 80 (T80) and Span<sup>®</sup> 80 (S80) as oil phase (O), surfactant (S) and cosurfactant (CoS). The nanoemulsions were characterised and their potential to enhance delivery was assessed using an in vitro skin model. Optimised nanoemulsion formulations were prepared based on EO (MUP-NE EO) and EU (MUP-NE EU) separately. MUP-NE EO had a smaller size with mean droplet diameter of 35.89 ± 0.68 nm and narrower particle size index (PDI) 0.10 ± 0.02 nm compared to MUP-NE EU. Both nanoemulsion formulations were stable at 25 °C for three months with the ability to enhance the transdermal permeation of MUP as compared to the control, Bactroban<sup>®</sup> cream. Inclusion of EU led to a two-fold increase in permeation of MUP compared to the control, while EO increased the percentage by 48% compared to the control. Additionally, more MUP was detected in the skin after 8 h following MUP-NE EU application, although MUP deposition from MUP-NE EO was higher after 24 h. It may be possible, through choice of essential oil to design nanoformulations for both acute and prophylactic management of topical infections.https://www.mdpi.com/1999-4923/15/2/378eucalyptus oileucalyptolmupirocinnanoemulsiontopical deliverypermeation |
| spellingShingle | Bahjat Alhasso Muhammad Usman Ghori Barbara R. Conway Development of Nanoemulsions for Topical Application of Mupirocin Pharmaceutics eucalyptus oil eucalyptol mupirocin nanoemulsion topical delivery permeation |
| title | Development of Nanoemulsions for Topical Application of Mupirocin |
| title_full | Development of Nanoemulsions for Topical Application of Mupirocin |
| title_fullStr | Development of Nanoemulsions for Topical Application of Mupirocin |
| title_full_unstemmed | Development of Nanoemulsions for Topical Application of Mupirocin |
| title_short | Development of Nanoemulsions for Topical Application of Mupirocin |
| title_sort | development of nanoemulsions for topical application of mupirocin |
| topic | eucalyptus oil eucalyptol mupirocin nanoemulsion topical delivery permeation |
| url | https://www.mdpi.com/1999-4923/15/2/378 |
| work_keys_str_mv | AT bahjatalhasso developmentofnanoemulsionsfortopicalapplicationofmupirocin AT muhammadusmanghori developmentofnanoemulsionsfortopicalapplicationofmupirocin AT barbararconway developmentofnanoemulsionsfortopicalapplicationofmupirocin |